INS and type 2 diabetes mellitus: Interestingly, pharmacological lowering of hepatic triglyceride content in type 2 diabetes by rosiglitazone, a PPARγ receptor agonist, is also associated with a significant increase in insulin clearance within 16 weeks, and this effect is present without significant weight loss [167].